TheGridNet
The Vienna Grid Vienna

Vienna
Breaking News

Live English Tutors
Restaurants Nouvelles Radars météo Répertoire

Meilleures histoires

Vienna Politics Nouvelles

Vienna is establishing a service point in the city hall
Vienna is establishing a service point in the city hall
Il y a 2 ans
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
Il y a 2 ans
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Il y a 2 ans
Austria sees sharp rise in acts of antisemitism
Austria sees sharp rise in acts of antisemitism
Il y a 2 ans
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Il y a 2 ans
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Il y a 2 ans
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Il y a 2 ans
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Il y a 2 ans
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Il y a 2 ans
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Il y a 2 ans